181 related articles for article (PubMed ID: 16285267)
1. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma.
Céruse P; Rabilloud M; Charrié A; Dubreuil C; Disant F
Ann Otol Rhinol Laryngol; 2005 Oct; 114(10):768-76. PubMed ID: 16285267
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
4. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
[TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
8. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen.
Yen TC; Lin WY; Kao CH; Cheng KY; Wang SJ
Clin Otolaryngol Allied Sci; 1998 Feb; 23(1):82-6. PubMed ID: 9563673
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.
Gauthé M; Richard-Molard M; Rigault E; Buecher B; Mariani P; Bellet D; Cacheux W; Lièvre A
BMC Cancer; 2018 Apr; 18(1):417. PubMed ID: 29653564
[TBL] [Abstract][Full Text] [Related]
10. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
11. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
12. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung.
Park SY; Lee JG; Kim J; Park Y; Lee SK; Bae MK; Lee CY; Kim DJ; Chung KY
Lung Cancer; 2013 Feb; 79(2):156-60. PubMed ID: 23206831
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck.
Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J
Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
16. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
17. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma.
Kimura Y; Fujieda S; Takabayashi T; Tanaka T; Sugimoto C; Saito H
Cancer Lett; 2000 Jul; 155(2):163-8. PubMed ID: 10822131
[TBL] [Abstract][Full Text] [Related]
18. Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer.
Kalfert D; Ludvikova M; Topolcan O; Windrichova J; Malirova E; Pesta M; Celakovsky P
Anticancer Res; 2014 Dec; 34(12):7431-41. PubMed ID: 25503184
[TBL] [Abstract][Full Text] [Related]
19. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
20. Early diagnosis of radiotherapy failure for patients with head and neck cancer: the role of biochemical markers.
Mrochem-Kwarciak J; Rutkowski T; Wygoda A; Deja R; Hajduk A; Składowski K
Tumori; 2018 Aug; 104(4):273-279. PubMed ID: 28604997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
